Having trouble accessing articles? Reset your cache.

Stealth cites endpoints in Phase III mitochondrial disease miss

Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III miss for its lead mitochondria-targeted therapy in primary mitochondrial myopathy, just two months after Alexion obtained an option to the candidate for

Read the full 392 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE